BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33416164)

  • 1. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis.
    Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W
    Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation.
    Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B
    Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia.
    Karabay AZ; Koc A; Ozkan T; Hekmatshoar Y; Altinok Gunes B; Sunguroglu A; Buyukbingol Z; Atalay A; Aktan F
    Hematology; 2018 Dec; 23(10):765-770. PubMed ID: 29945498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib.
    Hrdinova T; Toman O; Dresler J; Klimentova J; Salovska B; Pajer P; Bartos O; Polivkova V; Linhartova J; Machova Polakova K; Kabickova H; Brodska B; Krijt M; Zivny J; Vyoral D; Petrak J
    Int J Oncol; 2021 Feb; 58(2):238-250. PubMed ID: 33491750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA OIP5-AS1 Promotes the Autophagy-Related Imatinib Resistance in Chronic Myeloid Leukemia Cells by Regulating miR-30e-5p/ATG12 Axis.
    Dai H; Wang J; Huang Z; Zhang H; Wang X; Li Q; Feng W
    Technol Cancer Res Treat; 2021; 20():15330338211052150. PubMed ID: 34723728
    [No Abstract]   [Full Text] [Related]  

  • 8. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia.
    Zhang C; Shen L; Zhu Y; Xu R; Deng Z; Liu X; Ding Y; Wang C; Shi Y; Bei L; Wei D; Thorne RF; Zhang XD; Yu L; Chen S
    Theranostics; 2021; 11(6):2691-2705. PubMed ID: 33456567
    [No Abstract]   [Full Text] [Related]  

  • 10. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
    Wang XY; Sun GB; Wang YJ; Yan F
    Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
    Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells.
    Zhang J; Zhang M; Liang Y; Liu M; Huang Z
    Hematology; 2022 Dec; 27(1):43-52. PubMed ID: 34957936
    [No Abstract]   [Full Text] [Related]  

  • 13. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIF23 promotes autophagy-induced imatinib resistance in chronic myeloid leukaemia through activating Wnt/β-catenin pathway.
    Huang Y; Yuan C; Liu Q; Wang L
    Clin Exp Pharmacol Physiol; 2022 Dec; 49(12):1334-1341. PubMed ID: 36066385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia.
    Wang X; Rong S; Sun Y; Yin B; Yang X; Lu X; Sun H; Yan Y; Sun G; Liang Y; Wang P; Xie S; Li Y
    Oncol Rep; 2023 Aug; 50(2):. PubMed ID: 37350410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression.
    Huan C; Jin L; Heng W; Na A; Yuming P; Xin D; Qiaoxia Z
    Leuk Res; 2018 Dec; 75():1-6. PubMed ID: 30419548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CRISPR/Cas9-mediated microRNA-21 knockout increased imatinib sensitivity in chronic myeloid leukemia cells].
    Zhang Y; Wang LY; Li JZ; Jiang PF; Hu JD; Chen BY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):243-249. PubMed ID: 33910311
    [No Abstract]   [Full Text] [Related]  

  • 20. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
    Han SH; Korm S; Han YG; Choi SY; Kim SH; Chung HJ; Park K; Kim JY; Myung K; Lee JY; Kim H; Kim DW
    Autophagy; 2019 Dec; 15(12):2076-2090. PubMed ID: 30929559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.